Advertisement
Research Article

Keratinocyte Migration in the Developing Eyelid Requires LIMK2

  • Dennis S. Rice mail,

    drice@lexpharma.com

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Gwenn M. Hansen,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Feng Liu,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Mike J. Crist,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Matthew M. Newhouse,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • David Potter,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Nianhua Xu,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Alejandro Abuin,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Peter J. Vogel,

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    Current address: Department of Pathology, St. Jude Children's Research Hospital, Memphis, Tennessee, United States of America

    X
  • Brian P. Zambrowicz

    Affiliation: Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

    X
  • Published: October 05, 2012
  • DOI: 10.1371/journal.pone.0047168

About the Authors

Dennis S. Rice, Gwenn M. Hansen, Feng Liu, Mike J. Crist, Matthew M. Newhouse, David Potter, Nianhua Xu, Alejandro Abuin, Peter J. Vogel, Brian P. Zambrowicz
Lexicon Pharmaceuticals Incorporated, The Woodlands, Texas, United States of America

Corresponding Author

Email: drice@lexpharma.com

Competing Interests

Authors are/were employed by Lexicon Pharmaceuticals during the time at which this research was conducted and have received stock options from Lexicon Pharmaceuticals. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

Author Contributions

Conceived and designed the experiments: DSR GMH DP NX AA BPZ. Performed the experiments: DSR FL MJC MMN NX PV. Analyzed the data: DSR GMH DP AA BPZ. Contributed reagents/materials/analysis tools: BPZ. Wrote the paper: DSR GMH FL MJC MMN DP AA.